A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)

Conditions

• Diabetes, Type 2
• Obesity
• Overweight
• Overweight and/or Obesity
• Type 2 Diabetes

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• PF-08653944 — DRUG
  By Subcutaneous Injection
• Placebo — OTHER
  By Subcutaneous Injection

Study Details

The purpose of this clinical study is to learn about the safety and effects of the study medicine to help adults with obesity or overweight and type 2 diabetes lose weight. Being overweight or obese means carrying too much body weight. Type 2 diabetes is a condition where there is too much sugar in the blood. The study medicine is given by a shot under the skin in the belly area. The participants will be trained to do this at home once every week. About 660 out of 1000 adults will also receive the study medicine and about 330 out of 1000 adults will receive placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. The investigators will compare the experiences of people receiving the study medicine to those of the people who do not. This will help us assess if the study medicine is safe and effective. People will take part in this study for about 21 months. During this time, they will have about 14 study visits at the site and 5 over the phone.

Key Dates

Start date

Feb 24, 2026

Status verified

May 2026

Primary completion

Oct 12, 2027

Completion

May 16, 2028

Study Design

Enrollment

999 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Treatment Arm 1
  Participants will receive PF-08653944 by Subcutaneous Injection.
• Experimental: Treatment Arm 2
  Participants will receive PF-08653944 by Subcutaneous Injection.
• Experimental: Treatment Arm 3
  Participants will receive PF-08653944 by Subcutaneous Injection.
• Placebo Comparator: Placebo
  Participants will receive matching placebo by Subcutaneous Injection.

Primary Outcome Measure

Percent Change from baseline in body weight [ Time Frame: Baseline, Week 64 ]

Central Contacts

• Pfizer CT.gov Call Center
  1-800-718-1021
  [email protected]

Locations (35)

Find similar trials in Anaheim, CA

Related Studies

• Diabetes and Heart Disease Risk in Blacks
  Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
• Physical and Behavioral Traits of Overweight and Obese Adults
  Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
• Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
  Recruiting · National Heart, Lung, and Blood Institute (NHLBI) · Washington D.C., District of Columbia
• New Heart Imaging Techniques to Evaluate Possible Heart Disease
  Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland